<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82366">
  <stage>Registered</stage>
  <submitdate>20/10/2007</submitdate>
  <approvaldate>22/11/2007</approvaldate>
  <actrnumber>ACTRN12607000602426</actrnumber>
  <trial_identification>
    <studytitle>Bronchoscopic Vapour Therapy for Emphysema</studytitle>
    <scientifictitle>A First-in-Man Safety &amp; Feasibility Study of Bronchoscopic Thermal Vapour Ablation (BTVA) for Lung Volume Reduction in Patients with Heterogeneous Upper Lobe Emphysema (Phase 1)</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Emphysema</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Vapour (steam) is infused into a targeted emphysematous lung segment for approximately 4-8 seconds.  No more than 3 segments within 1 lobe of a lung will be treated.  The 3 segments will be treated in one procedure, with a waiting time of at least 4 minutes between each vapour treatment.  The total time of the BTVA procedure is expected to be 1.5 hours.</interventions>
    <comparator>Not Applicable - single group trial</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>All serious and non-serious events secondary to the BTVA procedure</outcome>
      <timepoint>Initiation through 6 months after intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pulmonary Function Status as measured by Forced Expiratory Volume in 1 second (FEV1) and Diffusing Capacity of Lung - carbon monoxide (DLCO).</outcome>
      <timepoint>3 and 6 months after intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Exercise capacity (6 minute walk test)</outcome>
      <timepoint>3 and 6 months after intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life (St. George Respiratory Questionnaire)</outcome>
      <timepoint>3 and 6 months after intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients diagnosed with heterogeneous emphysema with upper lobe predominance as evidence by Computed Tomography (CT) imaging

FEV1 &gt; 45% predicted; Total Lung Capacity (TLC) / 100% predicted; Residual Volume (RV) &gt; 150% predicted

Exercise Capacity:  Ability to walk &gt; 140 metres in 6 minutes after completing a pulmonary rehabilitation program

Non-smoking for 4 months prior to study enrollment

Dyspnea scoring &gt; or = 2 (of 4)</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients diagnosed with homogeneous emphysema or heterogeneous emphysema with lower lobe predominance

Known alpha-1 antityrpsin deficiency

Body Mass Index (BMI) &lt; 15kg/m2 or &gt; 35 kg/m2 - body mass index is the relationship between weight and height that is associated with body fat and health risk

Clinically significant asthma, chronic bronchitis or bronchiectasis

Patients with heart/lung transplant or prior lung volume reduction surgery

Patients with significant pulmonary hypertension, heart disease or history of stroke</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>22/10/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>4032</postcode>
    <postcode>3181</postcode>
    <postcode>5000</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Uptake Medical Corp.</primarysponsorname>
    <primarysponsoraddress>1942 1st Avenue
3rd FL
Seattle Washinton 98101</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Uptake Medical Corp</fundingname>
      <fundingaddress>1942 1st Avenue
3rd FL
Seattle Washinton 98101</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Novotech (Australia) Pty Limited</sponsorname>
      <sponsoraddress>Level 3
19 Harris Street
Pyrmont NSW 2009</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to established the side effect and benefit profile of BTVA in patients with heterogeneous upper lobe emphysema.  The results will help to support subsequent clinical trials in a larger patient sample.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Prince Charles Hospital</ethicname>
      <ethicaddress>Human Research Ethics Committee
The Prince Charles Hospital
Northside Health Service District
Rode Road
Chermside QLD 4032</ethicaddress>
      <ethicapprovaldate>14/09/2007</ethicapprovaldate>
      <hrec>EC2787</hrec>
      <ethicsubmitdate>31/08/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Alfred Hospital</ethicname>
      <ethicaddress>The Alfred Hospital Ethics Committee Office
Commercial Road
Melbourne Victoria 3004</ethicaddress>
      <ethicapprovaldate>12/11/2007</ethicapprovaldate>
      <hrec>ABN 27 318 956 319</hrec>
      <ethicsubmitdate>17/09/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Hopkins, MD, MBBS, FRACP</name>
      <address>Consultant Tranplant &amp; Thoracic Physician
Prince Charles Hospital
Private Practice Clinic
Rode Road
Chermisde QLD 4032</address>
      <phone>+61 7 31396486</phone>
      <fax />
      <email>Peter_Hopkins@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Pamela P. Simons, BS, RT(r)</name>
      <address>Vice-President
Clinical &amp; Regulatory Affairs
Clinical &amp; Regulatory Affairs Office
Uptake Medical Corp.
9688 63rd Avenue
Maple Grove
Minnesota 55369</address>
      <phone>+1 612 5641612</phone>
      <fax>+1 763 5365949</fax>
      <email>psimons@uptakemedical.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Pamela P. Simons, BS, RT(r)</name>
      <address>Vice-President
Clinical &amp; Regulatory Affairs
Clinical &amp; Regulatory Affairs Office
Uptake Medical Corp.
9688 63rd Avenue
Maple Grove
Minnesota 55369</address>
      <phone>+1 612 5641612</phone>
      <fax>+1 763 5365949</fax>
      <email>psimons@uptakemedical.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>